Literature DB >> 18184166

Evidence-based clinical practice Guidelines for Prostate Cancer (Summary - JUA 2006 Edition).

Sadao Kamidono, Shinichi Ohshima, Yoshihiko Hirao, Kazuhiro Suzuki, Yoichi Arai, Hiroyuki Fujimoto, Shin Egawa, Hideyuki Akaza, Isao Hara, Shiro Hinotsu, Yoshiyuki Kakehi, Tomonori Hasegawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18184166     DOI： 10.1111/j.1442-2042.2007.01959.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


× No keyword cloud information.
  9 in total

1.  Reduced glycosylation of α-dystroglycans on carcinoma cells contributes to formation of highly infiltrative histological patterns in prostate cancer.

Authors:  Hisashi Shimojo; Motohiro Kobayashi; Takayuki Kamigaito; Yasuyo Shimojo; Minoru Fukuda; Jun Nakayama
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

Review 2.  Degarelix: a review of its use in patients with prostate cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

3.  Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer.

Authors:  Takashi Kobayashi; Kent Kanao; Motoo Araki; Naoki Terada; Yasuyuki Kobayashi; Atsuro Sawada; Takahiro Inoue; Shin Ebara; Toyohiko Watanabe; Tomomi Kamba; Makoto Sumitomo; Yasutomo Nasu; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2017-11-11       Impact factor: 3.402

4.  Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy.

Authors:  Kazuhiro Matsumoto; Ryuichi Mizuno; Nobuyuki Tanaka; Hiroki Ide; Masanori Hasegawa; Masaru Ishida; Nozomi Hayakawa; Yota Yasumizu; Masayuki Hagiwara; Satoshi Hara; Eiji Kikuchi; Akira Miyajima; Ken Nakagawa; Yosuke Nakajima; So Nakamura; Jun Nakashima; Mototsugu Oya
Journal:  Med Oncol       Date:  2014-06-10       Impact factor: 3.064

Review 5.  Tissue biomarkers for prostate cancer radiation therapy.

Authors:  P T Tran; R K Hales; J Zeng; K Aziz; T Salih; R P Gajula; S Chettiar; N Gandhi; A T Wild; R Kumar; J M Herman; D Y Song; T L DeWeese
Journal:  Curr Mol Med       Date:  2012-07-01       Impact factor: 2.222

6.  Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

Authors:  Seung Hwan Lee; Mun Su Chung; Kyung Kgi Park; Chan Dong Yom; Dae Hoon Lee; Byung Ha Chung
Journal:  World J Urol       Date:  2011-07-16       Impact factor: 4.226

7.  Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management.

Authors:  Hideyuki Akaza; Choung Soo Kim; Peter Carroll; In Young Choi; Byung Ha Chung; Matthew R Cooperberg; Yoshihiko Hirao; Shiro Hinotsu; Shigeo Horie; Ji Youl Lee; Mikio Namiki; Chi-Fai Ng; Mizuki Onozawa; Seiichiro Ozono; Satoru Ueno; Rainy Umbas; Dingwei Ye; Gang Zhu
Journal:  Prostate Int       Date:  2014-06-30

8.  Prostate-specific Antigen as a Risk Factor for Skeletal Metastasis in Native Ethnic African Men with Prostate Cancer: A Case-control Study.

Authors:  Ayman M Qureshi; Khalid Makhdomi; William Stones
Journal:  World J Nucl Med       Date:  2017 Jan-Mar

Review 9.  Prostate cancer in East Asia: evolving trend over the last decade.

Authors:  Yao Zhu; Hong-Kai Wang; Yuan-Yuan Qu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.